Assenagon Asset Management
KDNY

Assenagon Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Assenagon Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,371,469
Closed -$31.7M – 1506
2023
Q1 		$31.7M Buy
1,371,469
+483,220
+54% +$11.5M 0.11% 160
2022
Q4 		$23.3M Sell
888,249
-543,145
-38% -$12M 0.08% 224
2022
Q3 		$28.1M Buy
1,431,394
+369,512
+35% +$7.41M 0.11% 186
2022
Q2 		$18.6M Buy
+1,061,882
New +$16.7M 0.07% 245
2020
Q2 		– Sell
-2,480
Closed -$34K – 1274
2020
Q1 		$34K Sell
2,480
-75,553
-97% -$893K ﹤0.01% 749
2019
Q4 		$460K Sell
78,033
-6,342
-8% -$34.5K ﹤0.01% 674
2019
Q3 		$447K Sell
84,375
-23,985
-22% -$159K ﹤0.01% 713
2019
Q2 		$834K Sell
108,360
-984
-0.9% -$15K 0.01% 756
2019
Q1 		$2.18M Buy
+109,344
New +$1.91M 0.02% 494

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Assenagon Asset Management's KDNY Position: Q2 2023 in Review

Assenagon Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 1,371,469 shares — an estimated $31.7M sold.

Assenagon Asset Management first reported a position in KDNY in Q1 2019 and held it in 9 quarters. The position peaked at $31.7M in Q1 2023. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • Assenagon Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Assenagon Asset Management sold 1,371,469 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $31.7M.
  • Assenagon Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2019 and held it in 9 quarters.
  • Assenagon Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $31.7M in Q1 2023.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Assenagon Asset Management's 13F filing for Q2 2023, filed 25 Jul 2023.